Neurelis, Inc.

Padagis petitioned for inter partes review of the '414 patent, challenging claims 1–18 as obvious over Gwozdz and Meezan. Trial was instituted, and the case remains pending with no final written decision.

Inter partes review challenging claims 1-22 of the '546 patent. The Board instituted review on September 16, 2025. Neurelis filed a statutory disclaimer disclaiming claims 1-16 and 18-21, leaving claims 17 and 22 at issue, and no Final Written Decision has yet issued.

IPR proceeding challenging the '786 patent; institution decision issued around July 16, 2025, and the proceeding is active.